HK1048593A1 - Techniques and compositions for treating cardiovascular disease by i in vivo /i gene delivery - Google Patents

Techniques and compositions for treating cardiovascular disease by i in vivo /i gene delivery

Info

Publication number
HK1048593A1
HK1048593A1 HK03100751.6A HK03100751A HK1048593A1 HK 1048593 A1 HK1048593 A1 HK 1048593A1 HK 03100751 A HK03100751 A HK 03100751A HK 1048593 A1 HK1048593 A1 HK 1048593A1
Authority
HK
Hong Kong
Prior art keywords
vivo
compositions
techniques
cardiovascular disease
gene delivery
Prior art date
Application number
HK03100751.6A
Other languages
Chinese (zh)
Inventor
Kirk Hammond H
J Giordano Frank
H Dillmann Wolfgang
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1048593A1 publication Critical patent/HK1048593A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
HK03100751.6A 1999-11-05 2003-01-29 Techniques and compositions for treating cardiovascular disease by i in vivo /i gene delivery HK1048593A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43515699A 1999-11-05 1999-11-05
US60908000A 2000-06-30 2000-06-30
PCT/US2000/030345 WO2001034208A1 (en) 1999-11-05 2000-11-03 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery

Publications (1)

Publication Number Publication Date
HK1048593A1 true HK1048593A1 (en) 2003-04-11

Family

ID=27030448

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100751.6A HK1048593A1 (en) 1999-11-05 2003-01-29 Techniques and compositions for treating cardiovascular disease by i in vivo /i gene delivery

Country Status (10)

Country Link
EP (1) EP1225921A1 (en)
JP (1) JP2003513942A (en)
KR (1) KR20020049031A (en)
CN (1) CN1433325A (en)
AU (1) AU784392B2 (en)
CA (1) CA2389524A1 (en)
EA (1) EA008538B1 (en)
HK (1) HK1048593A1 (en)
NZ (1) NZ546670A (en)
WO (1) WO2001034208A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389524A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
KR100562824B1 (en) 2002-03-20 2006-03-23 주식회사 바이로메드 Hybrid hepatocyte growth factor gene which has a high expression efficiency and expresses two heterotypes of hepatocyte growth factor
PL195457B1 (en) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Expression cassette, bi-cistron plasmide vector, pharmaceutical composition and their application
EP2460879A1 (en) * 2006-07-25 2012-06-06 Celladon Corporation Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
JP5248610B2 (en) * 2007-08-24 2013-07-31 ユーリウス−マクシミリアンス−ウニベルジテート ヴュルツブルク Mutant double cyclized receptor peptides that inhibit β1-adrenergic receptor antibodies
RU2470995C2 (en) 2008-04-09 2012-12-27 Вайромед Ко., Лтд. Lyophilised dna compounds for increased plasmid dna expression
EP2385840A4 (en) * 2009-01-07 2012-12-12 Vegenics Pty Ltd Materials and methods for the treatment of hypertension
KR101006106B1 (en) * 2009-06-04 2011-01-07 김현태 Heat wire for isolating electromagnetic field
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
HUE036640T2 (en) * 2012-02-14 2018-07-30 Univ California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
WO2013184782A2 (en) 2012-06-05 2013-12-12 Muffin Incorporated Catheter systems and methods useful for cell therapy
BR112016008267A2 (en) 2013-10-22 2017-10-03 Viromed Co Ltd Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
US20210393805A1 (en) * 2018-05-16 2021-12-23 University Of Massachusetts Perfusion-based delivery of recombinant aav vectors for expression of secreted proteins
KR20210027493A (en) 2018-07-19 2021-03-10 주식회사 헬릭스미스 Freeze-dried pharmaceutical composition for naked DNA gene therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188575A1 (en) * 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
ATE279518T1 (en) * 1997-01-29 2004-10-15 Cornell Res Foundation Inc ADMINISTRATION OF ADENOVIRUS VECTOR AT DIFFERENT PLACES TO INDUCE ANGIOGENESIS
WO1998050079A2 (en) * 1997-05-06 1998-11-12 The Regents Of The University Of California Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
AU2663799A (en) * 1998-02-11 1999-08-30 Regents Of The University Of California, The Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery
EP1139751A4 (en) * 1998-12-28 2003-03-19 Arch Dev Corp Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
CA2389524A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery

Also Published As

Publication number Publication date
CA2389524A1 (en) 2001-05-17
EA008538B1 (en) 2007-06-29
KR20020049031A (en) 2002-06-24
NZ546670A (en) 2009-02-28
JP2003513942A (en) 2003-04-15
EP1225921A1 (en) 2002-07-31
AU784392B2 (en) 2006-03-23
CN1433325A (en) 2003-07-30
EA200200533A1 (en) 2002-12-26
WO2001034208A1 (en) 2001-05-17
AU1460401A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
AU2002305346A1 (en) Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
AU3692001A (en) Compositions and methods for enhancing drug delivery across biological membranesand tissues
HK1048593A1 (en) Techniques and compositions for treating cardiovascular disease by i in vivo /i gene delivery
IL144508A0 (en) Compositions and methods for use in targeting vascular destruction
IL144325A0 (en) Compositions and methods for mucosal delivery
MXPA03007590A (en) Compositions and methods for enhancing drug delivery across and into ocular tissues.
PL338846A1 (en) Starch compositions suitable for treatment in molten state
HK1080724A1 (en) Stabilized pharmaceutical composition in lyophilized form
HUP0200409A3 (en) Valdecoxib compositions, process for their preparation and their use
EP1545578A4 (en) Compositions and methods for treating cardiovascular disease
EP1165586A4 (en) TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS
HUP0203590A3 (en) Remedies for diseases in association with decrease in bone mass
HUP0200275A3 (en) Seed treatment composition and preparation thereof
EP1180006A4 (en) Compositions and methods for their preparation from lepidium
EP1470240A4 (en) Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747,1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165,2
MXPA02003232A (en) Compositions and methods for altering gene expression.
EP1583966A4 (en) Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32
EP1233671A4 (en) Compositions and methods for drug delivery using amphiphile binding molecules
AU2002306461A1 (en) In vivo delivery methods and compositions
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
IL148946A0 (en) Altering gene expression with ssdna produced in vivo
IL149451A0 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
ZA200203303B (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery.
AU2002226986A1 (en) In vivo delivery methods and compositions
HU0103686D0 (en) Pharmaceutical composition for preventing or treating diseases associated with an excess in il-12 production